Exact Sciences Corp (NAS:EXAS)
$ 53.52 2.52 (4.94%) Market Cap: 9.88 Bil Enterprise Value: 11.78 Bil PE Ratio: 0 PB Ratio: 3.14 GF Score: 78/100

Exact Sciences Corp at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 12, 2020 / 06:30PM GMT
Release Date Price: $87.15 (+4.15%)
Max Masucci
Canaccord Genuity Corp., Research Division - Associate

Hi. Welcome to the 40th Annual Canaccord Genuity Global Growth Conference. I'm Max Masucci, lead diagnostics analyst at Canaccord. And I'm pleased to be joined by Exact Sciences, one of the fastest-growing companies in my coverage universe over the past 5 years. And one of the biggest success stories in noninvasive screening for early-stage cancer due to its Cologuard test for colorectal cancer. So despite growing its Cologuard business from under $2 million in revenues in 2014 to over $810 million in 2020, Exact remains just 6% penetrated in its Cologuard opportunity with a stated goal of achieving 40% penetration over time. Beyond Cologuard, Exact has a Precision Oncology segment which it acquired in 2018 through its acquisition of Genomic Health. Exact is a market-leading R&D engine, which we expect to drive shareholder returns equally as spectacularly as what we have seen over the past 5 years. So I'm really pleased to welcome back Exact Sciences CFO, Jeff Elliott; and Megan Jones, Investor Relations. Thanks again for joining us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot